ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
About Alnylam Pharmaceuticals, Inc. - Common Stock Company overview from Wikipedia
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Read more
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
ALNY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ALNY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
ALNY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 8 21.6%
- Buy 21 56.8%
- Hold 8 21.6%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
24 analysts · 2026-08-14Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $1.21 | $1.59 | -0.38% |
| March 31, 2026 | $1.51 | $0.98 | 0.53% |
| Dec. 31, 2025 | $0.82 | $1.15 | -0.33% |
| Sept. 30, 2025 | $2.11 | $0.76 | 1.3% |
| June 30, 2025 | $-0.51 | $-0.73 | 0.22% |
| March 31, 2025 | $-0.44 | $-1.03 | 0.59% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
Balance Sheet 23
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
Cash Flow 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
Liquidity & Solvency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
Income Statement 17
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
Balance Sheet 22
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
Cash Flow 12
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
Liquidity & Solvency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
Efficiency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
Valuation (TTM) 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| Operating Margin % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M |
| Diluted EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 877 filers · $27.1B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 99 (-11 vs prior Q) | 77 (-68 vs prior Q) | 328 (+4 vs prior Q) | 259 (+4 vs prior Q) | +15.9M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Capital World Investors | $3,354,715,611 | 11,144,846 | 12.36% | Shares |
| FMR LLC | $3,108,157,652 | 10,325,076 | 11.45% | Shares |
| Capital Research Global Investors | $2,935,115,324 | 9,750,699 | 10.81% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,968,251,542 | 6,538,390 | 7.25% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,815,053,762 | 6,029,478 | 6.69% | Shares |
| STATE STREET CORP | $1,070,369,060 | 3,555,689 | 3.94% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $686,853,582 | 2,288,725 | 2.53% | Shares |
| NORGES BANK | $683,883,867 | 2,271,813 | 2.52% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $614,923,915 | 2,042,733 | 2.26% | Shares |
| Dodge & Cox | $588,631,955 | 1,955,393 | 2.17% | Shares |
| TWO SIGMA INVESTMENTS, LP | $564,713,315 | 1,875,937 | 2.08% | Shares |
| AMERICAN CENTURY COMPANIES INC | $558,098,292 | 1,853,956 | 2.06% | Shares |
| TWO SIGMA ADVISERS, LP | $450,362,484 | 1,132,560 | 1.66% | Shares |
| Clearbridge Investments, LLC | $379,142,285 | 1,259,483 | 1.40% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269,059,154 | 893,795 | 0.99% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $259,723,265 | 862,782 | 0.96% | Shares |
| Deep Track Capital, LP | $248,349,750 | 825,000 | 0.91% | Shares |
| Qube Research & Technologies Ltd | $240,437,176 | 798,715 | 0.89% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219,642,021 | 729,635 | 0.81% | Shares |
| BANK OF AMERICA CORP /DE/ | $176,408,397 | 586,016 | 0.65% | Shares |
| LOOMIS SAYLES & CO L P | $170,456,431 | 566,244 | 0.63% | Shares |
| BAILLIE GIFFORD & CO | $165,849,468 | 550,940 | 0.61% | Shares |
| ROYAL BANK OF CANADA | $154,998,000 | 514,893 | 0.57% | Shares |
| Polar Capital Holdings Plc | $145,322,534 | 482,751 | 0.54% | Shares |
| Paradigm Biocapital Advisors LP | $144,494,400 | 480,000 | 0.53% | Shares |
| D. E. Shaw & Co., Inc. | $129,533,209 | 430,300 | 0.48% | Call option |
| FIRST TRUST ADVISORS LP | $126,894,361 | 421,534 | 0.47% | Shares |
| Swiss National Bank | $112,609,302 | 374,080 | 0.41% | Shares |
| WELLS FARGO & COMPANY/MN | $111,381,100 | 370,000 | 0.41% | Call option |
| BlackRock, Inc. | $102,807,465 | 341,519 | 0.38% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $100,618,073 | 334,246 | 0.37% | Shares |
| Sumitomo Mitsui Trust Group, Inc. | $97,948,840 | 325,379 | 0.36% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97,804,647 | 324,900 | 0.36% | Call option |
| Legal & General Group Plc | $97,467,493 | 323,780 | 0.36% | Shares |
| MILLENNIUM MANAGEMENT LLC | $95,125,781 | 316,001 | 0.35% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $94,687,695 | 314,546 | 0.35% | Shares |
| Candriam S.C.A. | $94,586,456 | 314,512 | 0.35% | Shares |
| D. E. Shaw & Co., Inc. | $93,229,593 | 309,702 | 0.34% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90,367,000 | 300,193 | 0.33% | Shares |
| DEUTSCHE BANK AG\ | $89,849,026 | 298,472 | 0.33% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88,641,294 | 294,460 | 0.33% | Shares |
| Pictet Asset Management Holding SA | $83,257,214 | 278,613 | 0.31% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $81,586,054 | 271,023 | 0.30% | Shares |
| GILDER GAGNON HOWE & CO LLC | $80,992,374 | 269,051 | 0.30% | Shares |
| CONGRESS ASSET MANAGEMENT CO | $79,983,972 | 265,701 | 0.29% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $77,578,441 | 257,710 | 0.29% | Shares |
| California Public Employees Retirement System | $76,477,575 | 254,053 | 0.28% | Shares |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75,974,872 | 252,383 | 0.28% | Shares |
| Korea Investment CORP | $74,553,090 | 247,660 | 0.27% | Shares |
| Woodline Partners LP | $74,138,270 | 246,282 | 0.27% | Shares |
| Squarepoint Ops LLC | $70,440,719 | 233,999 | 0.26% | Shares |
| TD Asset Management Inc | $70,349,507 | 233,696 | 0.26% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65,136,061 | 196,863 | 0.24% | Shares |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64,296,696 | 213,589 | 0.24% | Shares |
| National Pension Service | $59,692,744 | 198,295 | 0.22% | Shares |
| PINEBRIDGE INVESTMENTS LLC | $58,914,280 | 195,709 | 0.22% | Shares |
| Robeco Institutional Asset Management B.V. | $56,618,929 | 188,084 | 0.21% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53,824,164 | 178,800 | 0.20% | Put option |
| VICTORY CAPITAL MANAGEMENT INC | $52,030,628 | 172,842 | 0.19% | Shares |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50,772,924 | 168,664 | 0.19% | Shares |
| RHUMBLINE ADVISERS | $49,844,185 | 165,579 | 0.18% | Shares |
| Life Cycle Investment Partners Ltd | $49,797,587 | 165,424 | 0.18% | Shares |
| ANTIPODES PARTNERS Ltd | $49,228,339 | 163,533 | 0.18% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47,228,883 | 157,223 | 0.17% | Shares |
| CAPITAL FUND MANAGEMENT S.A. | $46,931,781 | 155,904 | 0.17% | Shares |
| Assenagon Asset Management S.A. | $46,868,866 | 155,695 | 0.17% | Shares |
| Vinva Investment Management Ltd | $45,487,381 | 154,972 | 0.17% | Shares |
| JANUS HENDERSON GROUP PLC | $43,671,202 | 132,000 | 0.16% | Shares |
| Hudson Bay Capital Management LP | $42,204,406 | 140,200 | 0.16% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $41,059,106 | 136,395 | 0.15% | Shares |
| ProShare Advisors LLC | $38,686,569 | 128,514 | 0.14% | Shares |
| GOLDMAN SACHS GROUP INC | $37,029,700 | 123,010 | 0.14% | Shares |
| LMR Partners LLP | $35,881,572 | 119,196 | 0.13% | Shares |
| Man Group plc | $35,798,187 | 118,919 | 0.13% | Shares |
| HSBC HOLDINGS PLC | $35,754,282 | 120,600 | 0.13% | Put option |
| SCS Capital Management LLC | $34,783,715 | 115,549 | 0.13% | Shares |
| AVIVA PLC | $34,477,568 | 114,532 | 0.13% | Shares |
| Davern Capital Partners, LP | $34,041,978 | 113,085 | 0.13% | Shares |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33,770,750 | 112,184 | 0.12% | Shares |
| Longaeva Partners L.P. | $33,191,869 | 110,261 | 0.12% | Shares |
| 683 Capital Management, LLC | $32,360,725 | 107,500 | 0.12% | Put option |
| MARSHALL WACE, LLP | $32,215,929 | 107,019 | 0.12% | Shares |
| HighTower Advisors, LLC | $31,621,666 | 105,045 | 0.12% | Shares |
| Bridgewater Associates, LP | $29,977,772 | 99,584 | 0.11% | Shares |
| Prosight Management, LP | $29,525,022 | 98,080 | 0.11% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28,956,123 | 96,408 | 0.11% | Shares |
| Andra AP-fonden | $28,685,436 | 86,697 | 0.11% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28,376,894 | 94,266 | 0.10% | Shares |
| AMERIPRISE FINANCIAL INC | $28,191,159 | 93,649 | 0.10% | Shares |
| BARCLAYS PLC | $27,979,234 | 92,945 | 0.10% | Shares |
| TREMBLANT CAPITAL GROUP | $27,977,728 | 92,940 | 0.10% | Shares |
| FIL Ltd | $27,652,616 | 91,860 | 0.10% | Shares |
| Balyasny Asset Management L.P. | $26,945,195 | 89,510 | 0.10% | Shares |
| Caisse de depot et placement du Quebec | $25,812,720 | 85,748 | 0.10% | Shares |
| Mitsubishi UFJ Trust & Banking Corp | $24,911,136 | 82,753 | 0.09% | Shares |
| RAYMOND JAMES FINANCIAL INC | $24,661,883 | 81,925 | 0.09% | Shares |
| CITADEL ADVISORS LLC | $24,564,048 | 81,600 | 0.09% | Call option |
| VANGUARD GROUP INC | $24,356,460 | 61,251 | 0.09% | Shares |
| NEOS Investment Management LLC | $23,562,822 | 78,274 | 0.09% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $23,444,213 | 80,462 | 0.09% | Shares |
Company insiders 41 insiders · 1 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | April 6, 2026 S | 9,443 | 0 | 14 | $-1,274,343 |
| Colleen F Reitan | Director | May 20, 2026 A | 1,446 | 0 | 0 | $0 |
| Charles Elliott Sigal | Director | May 20, 2026 A | 1,446 | 0 | 0 | $0 |
| Stuart A Arbuckle | Director | May 20, 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | Director | May 20, 2026 A | 1,446 | 0 | 0 | $0 |
| Amy Schulman | Director | May 20, 2026 A | 24,049 | 0 | 0 | $0 |
| Dennis A Ausiello | Director | May 20, 2026 A | 1,582 | 0 | 0 | $0 |
| Margaret A Hamburg | Director | May 20, 2026 A | 1,582 | 0 | 0 | $0 |
| KELLOGG PETER N | Director | May 20, 2026 A | 1,446 | 0 | 0 | $0 |
| David E I Pyott | Director | May 20, 2026 A | 1,582 | 0 | 0 | $0 |
| Victor J Dzau | Director | June 21, 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | Director | June 1, 2006 A | 5,293 | 0 | 0 | $0 |
| John E Berriman | Director | June 8, 2005 A | 2,475 | 0 | 0 | $0 |
| Christoph H Westphal | Director | June 3, 2004 C | 2,409,970 | 0 | 0 | $0 |
| Sanofi | 10% owner | May 31, 2017 P | 10,554,134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | 10% owner | Feb. 23, 2016 S | 4,896,716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10% owner | June 3, 2004 C | 2,409,970 | 0 | 0 | $0 |
| CHP II LP | 10% owner | May 27, 2004 P | 232,500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | Aug. 10, 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | Aug. 10, 2018 A | 9,030 | 0 | 0 | $0 |
| John Maraganore | — | Aug. 10, 2018 A | 151,297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | March 9, 2018 M | 140,795 | 0 | 0 | $0 |
| Michael Mason | — | Jan. 4, 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | Dec. 29, 2017 M | 14,500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | Dec. 20, 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | Dec. 20, 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | Nov. 19, 2015 G | 306,996 | 0 | 0 | $0 |
| Marsha Fanucci | — | June 1, 2015 A | 10,000 | 0 | 0 | $0 |
| Steven M Paul | — | June 1, 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | June 1, 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | June 1, 2015 A | 2,091,868 | 0 | 0 | $0 |
| Kevin P Starr | — | June 1, 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | May 19, 2014 M | 3,905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | Dec. 8, 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | Dec. 8, 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | June 18, 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | June 2, 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | June 11, 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | Dec. 9, 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | Dec. 7, 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | June 3, 2004 C | 18,745 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 filings | Feb. 14, 2007 | — | Initial filing | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | Feb. 15, 2006 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 150 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3.25% | 53,807 SH | Aug. 8, 2026 | Daily |
| NUMG · Nushares ETF Trust | 3.23% | 36,910 NS | April 30, 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3.19% | 10,523 NS | May 31, 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2.79% | 3,791 NS | May 31, 2026 | N-PORT |
| IBB · iShares Trust | 2.21% | 976,319 SH | Aug. 8, 2026 | Daily |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2.01% | 3,468 NS | April 30, 2026 | N-PORT |
| BIB · ProShares Trust | 2.01% | 4,904 NS | May 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.99% | 7,268 SH | Aug. 8, 2026 | Daily |
| FDG · AMERICAN CENTURY ETF TRUST | 1.94% | 26,515 NS | May 31, 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1.40% | 824 NS | April 30, 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1.29% | 15,623 NS | April 30, 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.24% | 2,379 NS | April 30, 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1.14% | 1,954 NS | May 31, 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1.08% | 966 NS | April 30, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.90% | 15,151 NS | April 30, 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0.89% | 35,072 NS | April 30, 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0.88% | 1,022,888 SH | Aug. 8, 2026 | Daily |
| IWP · iShares Trust | 0.82% | 770,414 SH | Aug. 8, 2026 | Daily |
| JOET · Virtus ETF Trust II | 0.80% | 6,062 NS | April 30, 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0.76% | 613,330 NS | May 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.66% | 60,901 NS | April 30, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.59% | 398,693 SH | Aug. 8, 2026 | Daily |
| FFLG · FIDELITY COVINGTON TRUST | 0.58% | 11,032 NS | April 30, 2026 | N-PORT |
| QNXT · iShares Trust | 0.54% | 699 SH | Aug. 8, 2026 | Daily |
| USMV · iShares Trust | 0.47% | 527,555 SH | Aug. 8, 2026 | Daily |
| IYH · iShares Trust | 0.47% | 79,894 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.45% | 1,532,109 SH | Aug. 8, 2026 | Daily |
| UPSD · ETF Series Solutions | 0.44% | 1,435 NS | April 30, 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0.43% | 4,118 NS | May 31, 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0.39% | 6,430 NS | April 30, 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.39% | 2,893,468 SH | Aug. 8, 2026 | Daily |
| IMCG · iShares Trust | 0.38% | 72,243 SH | Aug. 8, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.38% | 10,723 NS | April 30, 2026 | N-PORT |
| ESMV · iShares Trust | 0.35% | 128 SH | Aug. 8, 2026 | Daily |
| SDG · iShares Trust | 0.33% | 2,658 SH | Aug. 8, 2026 | Daily |
| SMIZ · Zacks Trust | 0.31% | 2,688 NS | May 31, 2026 | N-PORT |
| ESLG · Strategy Shares | 0.31% | 196 NS | April 30, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.31% | 112 NS | April 30, 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.30% | 305 NS | April 30, 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.28% | 94 NS | May 31, 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.26% | 404 NS | April 30, 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.24% | 2,252 NS | April 30, 2026 | N-PORT |
| ESUM · Strategy Shares | 0.23% | 1,141 NS | April 30, 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0.23% | 45,231 NS | April 30, 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 15,559 NS | April 30, 2026 | N-PORT |
| QCLR · Global X Funds | 0.21% | 27 NS | April 30, 2026 | N-PORT |
| QYLG · Global X Funds | 0.21% | 953 NS | April 30, 2026 | N-PORT |
| IWR · iShares Trust | 0.21% | 542,695 SH | Aug. 8, 2026 | Daily |
| QRMI · Global X Funds | 0.21% | 108 NS | April 30, 2026 | N-PORT |
| QYLD · Global X Funds | 0.20% | 54,832 NS | April 30, 2026 | N-PORT |